NEVVI Medicare utilization intelligence
CMS RBCS · Durable medical equipment · Drugs Administered Through DME

Bronchodilator codes

8 CPT®/HCPCS codes, ranked by est. all-Medicare services — scaled from national Medicare Part B fee-for-service volume. Open any code for the full market view — ranked physician groups, geography, and 12-year trend.

CY2024 · National scale is an all-Medicare estimate · est. — scaled estimate — assumes MA utilization mirrors FFS; not an observation; the observed fee-for-service figure is shown adjacent. Part B · national figures

HCPCS · Drugs Administered Through DME J7613 Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg CMS descriptor · HCPCS
Medicare Part B claims
First observed 2013 — start of our 12-year window; the code predates it
National scale 135,072 services · est. ▲ 1.9% YoY · 29,087 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 67,884 observed fee-for-service services
See the national market for J7613 → ranked groups · states · 12-yr trend
HCPCS · Drugs Administered Through DME J7620 Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme CMS descriptor · HCPCS
Medicare Part B claims
First observed 2013 — start of our 12-year window; the code predates it
National scale 67,036 services · est. ▲ 10.3% YoY · 25,715 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 33,315 observed fee-for-service services
See the national market for J7620 → ranked groups · states · 12-yr trend
HCPCS · Drugs Administered Through DME J7611 Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg CMS descriptor · HCPCS
Medicare Part B claims
First observed 2013 — start of our 12-year window; the code predates it
National scale 21,924 services · est. ▲ 13.4% YoY · 3,959 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 10,935 observed fee-for-service services
See the national market for J7611 → ranked groups · states · 12-yr trend
HCPCS · Drugs Administered Through DME J7644 Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram CMS descriptor · HCPCS
Medicare Part B claims
First observed 2013 — start of our 12-year window; the code predates it
National scale 11,042 services · est. ▼ 7.8% YoY · 4,586 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 5,496 observed fee-for-service services
See the national market for J7644 → ranked groups · states · 12-yr trend
HCPCS · Drugs Administered Through DME J7614 Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 0.5 mg CMS descriptor · HCPCS
Medicare Part B claims
First observed 2013 — start of our 12-year window; the code predates it
National scale 8,352 services · est. ▲ 0.1% YoY · 1,634 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 4,145 observed fee-for-service services
See the national market for J7614 → ranked groups · states · 12-yr trend
HCPCS · Drugs Administered Through DME J7612 Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 0.5 mg CMS descriptor · HCPCS
Medicare Part B claims
First observed 2013 — start of our 12-year window; the code predates it
National scale 816 services · est. ▲ 75.0% YoY · 260 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 407 observed fee-for-service services
See the national market for J7612 → ranked groups · states · 12-yr trend
HCPCS · Drugs Administered Through DME J7606 Formoterol fumarate, inhalation solution, fda approved final product, non-compounded, administered through dme, unit dose form, 20 micrograms CMS descriptor · HCPCS
Medicare Part B claims
First observed 2013 — start of our 12-year window; the code predates it
National scale 215 services · est. ▲ 20.5% YoY · 42 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 107 observed fee-for-service services
See the national market for J7606 → ranked groups · states · 12-yr trend
HCPCS · Drugs Administered Through DME J7677 Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram CMS descriptor · HCPCS
Medicare Part B claims
First observed 2020 — first year this code appears in Part B claims
National scale 60 services · est. ▲ 82.8% YoY · 25 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 30 observed fee-for-service services
See the national market for J7677 → ranked groups · states · 12-yr trend